ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2007
Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 179 citations in OpenAlex.
- Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.The Journal of clinical investigation · 2022Trial
- Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.Leukemia & lymphoma · 2008Trial
- Fundamental prognostic difference of ATM gene mutation and deletion in newly diagnosed mantle cell lymphoma.Molecular medicine (Cambridge, Mass.) · 2025Article
- Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma.Cancers · 2022Article
- Article
- The pathologic diagnosis of mantle cell lymphoma.Histology and histopathology · 2021Review
- Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.Scientific reports · 2021Article
- Molecular Pathogenesis of Mantle Cell Lymphoma.Hematology/oncology clinics of North America · 2020Review
- Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.Nature medicine · 2019Article
- Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.Current oncology reports · 2018Review
- The role of B cell antigen receptors in mantle cell lymphoma.Journal of hematology & oncology · 2017Review
- Expansion of BCR/ABL1British journal of haematology · 2017Article
- Review
- Article
- Mantle cell lymphoma--a spectrum from indolent to aggressive disease.Virchows Archiv : an international journal of pathology · 2016Review
- High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival.Oncotarget · 2015Article
- SNPs Array Karyotyping in Non-Hodgkin Lymphoma.Microarrays (Basel, Switzerland) · 2015Review
- De Novo CD5 Negative Blastic Mantle Cell Lymphoma Presented with Massive Bone Marrow Necrosis without Adenopathy or Organomegaly.Case reports in hematology · 2015Article
- Self-digitization microfluidic chip for absolute quantification of mRNA in single cells.Analytical chemistry · 2014Article
- Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis.Nature medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo compare the genetic relationship between cyclin D1-positive and cyclin D1-negative mantle cell lymphomas (MCLs) and to determine whether specific genetic alterations may add prognostic information to survival prediction based on the proliferation signature of MCLs. PATIENTS AND
methodsSeventy-one cyclin D1-positive and six cyclin D1-negative MCLs previously characterized by gene expression profiling were examined by comparative genomic hybridization (CGH).
resultsCyclin D1-negative MCLs were genetically characterized by gains of 3q, 8q, and 15q, and losses of 1p, 8p23-pter, 9p21-pter, 11q21-q23, and 13q that were also the most common alterations in conventional MCLs. Parallel analysis of CGH aberrations and locus-specific gene expression profiles in cyclin D1-positive patients showed that chromosomal imbalances had a substantial impact on the expression levels of the genes located in the altered regions. The analysis of prognostic factors revealed that the proliferation signature, the number of chromosomal aberrations, gains of 3q, and losses of 8p, 9p, and 9q predicted survival of MCL patients. A multivariate analysis showed that the gene expression-based proliferation signature was the strongest predictor for shorter survival. However, 3q gains and 9q losses provided prognostic information that was independent of the proliferative activity.
conclusionCyclin D1-positive and -negative MCLs share the same secondary genetic aberrations, supporting the concept that they correspond to the same genetic entity. The integration of genetic information on chromosome 3q and 9q alterations into a proliferation signature-based model may improve the ability to predict survival in patients with MCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.